James W. Chu

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

Tracey McLaughlin, Fahim Abbasi, Karen Cheal et al. · Annals of Internal Medicine · 2003 · 1K citations

Medicine, Endocrinology, Diabetology +13

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin

Fahim Abbasi, James W. Chu, Cindy Lamendola et al. · Diabetes · 2004 · 244 citations · Full text

Medicine, Endocrinology, Human Nutrition +12

Successful Long-Term Treatment of Refractory Cushing’s Disease with High-Dose Mifepristone (RU 486)

James W. Chu, Dwight F. Matthias, Joseph K. Belanoff et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 189 citations · Full text

Medicine, Endocrinology, Pharmacology +17

High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension

James W. Chu, Peter N. Kao, John L. Faul et al. · CHEST Journal · 2002 · 176 citations

Medicine, Endocrinology, Internal Medicine +13